网站开发价格表,做网站一屏的尺寸是,有哪些做文创产品的网站,电商运营主要负责什么9D9-CP008单克隆抗体是原始9D9单克隆抗体的重组嵌合型抗体。可变结构域序列与原始9D9克隆号相同#xff0c;但是恒定区序列已经从小鼠IgG2b变为小鼠IgG2a。9D9-CP008单克隆抗体在Fc片段中也含有LALA-PG突变#xff0c;使其无法与内源性Fcγ受体结合。 9D9-CP008单克隆抗体能与…9D9-CP008单克隆抗体是原始9D9单克隆抗体的重组嵌合型抗体。可变结构域序列与原始9D9克隆号相同但是恒定区序列已经从小鼠IgG2b变为小鼠IgG2a。9D9-CP008单克隆抗体在Fc片段中也含有LALA-PG突变使其无法与内源性Fcγ受体结合。 9D9-CP008单克隆抗体能与小鼠CTLA-4(细胞毒性T淋巴细胞抗原-4)反应CTLA-4也称为CD152。CTLA-4是一种33 kDa的细胞表面受体由属于免疫球蛋白超家族CD28家族的Ctla4基因编码。CTLA-4在活化的T淋巴细胞和B淋巴细胞上表达。CTLA-4在结构上类似于T细胞共刺激蛋白CD28两种分子都与B7家族成员B7-1 (CD80)和B7-2 (CD86)结合。在与配体结合时CTLA-4负调节细胞介导的免疫反应。CTLA-4在诱导和/或维持免疫耐受、胸腺细胞发育和保护性免疫调节中起作用。CTLA-4在免疫下调中的关键作用已经在CTLA-4缺陷小鼠中得到证实这些小鼠在3-5周龄时由于淋巴增生性疾病的发展而死亡。CTLA-4目前是肿瘤免疫治疗中的热门免疫检查点靶点之一。 产品详情 产品名称 RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)/欣博盛生物 产品货号 CP008 产品规格 1mg 反应种属 Mouse 克隆号 9D9-CP008 同种型 Mouse IgG2b(switched from mouse IgG2a) 免疫原 Not available or unknown 实验应用 in vivo CTLA-4 neutralization* Western blot* *Reported for the original mouse IgG2b 9D9 antibody 产品形式 PBS, pH 7.0,Contains no stabilizers or preservatives 纯度 95%, Determined by SDS-PAGE 聚合 5%, Determined by SEC 无菌处理 0.2 µm filtration 纯化方式 Protein A 分子量 150 kDa 小鼠病原检测 Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative 保存条件 抗体原液保存在4°C不能冷冻保存。 推荐抗体稀释液 InVivoPure pH 7.0 Dilution Buffer货号IP0070/欣博盛生物 该产品自上市已被多篇SCI文献引用品质有保证以下是部分已发表的文献引用 应用 文章 体内CTLA-4中和 (in vivo CTLA-4 neutralization) 1. Dai, M., et al. (2015). Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies Clin Cancer Res 21(5): 1127-1138. 2. Zippelius, A., et al. (2015). Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment Cancer Immunol Res 3(3): 236-244. 3. Redmond, W. L., et al. (2014). Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity Cancer Immunol Res 2(2): 142-153. 4. Condamine, T., et al. (2014). ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis J Clin Invest 124(6): 2626-2639. 5. Muller, P., et al. (2014). Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells Cancer Immunol Res 2(8): 741-755. 6. Bulliard, Y., et al. (2013). Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies J Exp Med 210(9): 1685-1693.
